Namodenoson

Namodenoson
Clinical data
Other names	Chloro-IB-MECA; 2-Cl-IB-MECA
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (2S,3S,4R,5R)-5-[2-Chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-N-methyloxolane-2-carboxamide;
CAS Number	163042-96-4;
PubChem CID	3035850;
IUPHAR/BPS	457;
DrugBank	DB12885;
ChemSpider	2299989;
UNII	Z07JR07J6C;
KEGG	D11128;
ChEMBL	ChEMBL431733;
CompTox Dashboard (EPA)	DTXSID80167504 ;
ECHA InfoCard	100.162.091
Chemical and physical data
Formula	C18H18ClIN6O4
Molar mass	544.73 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)Cl)NCC4=CC(=CC=C4)I)O)O;
	InChI InChI=1S/C18H18ClIN6O4/c1-21-16(29)13-11(27)12(28)17(30-13)26-7-23-10-14(24-18(19)25-15(10)26)22-6-8-3-2-4-9(20)5-8/h2-5,7,11-13,17,27-28H,6H2,1H3,(H,21,29)(H,22,24,25)/t11-,12+,13-,17+/m0/s1; Key:IPSYPUKKXMNCNQ-PFHKOEEOSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease,^[1] liver cancer,^[2] and pancreatic cancer.^[3]

References

^ Safadi, Rifaat; Braun, Marius; Francis, Adi; Milgrom, Yael; Massarwa, Muhammad; Hakimian, David; Hazou, Wadi; Issachar, Assaf; Harpaz, Zivit; Farbstein, Motti; Itzhak, Inbal; Lev-Cohain, Naama; Bareket-Samish, Avital; Silverman, Michael H.; Fishman, Pnina (December 2021). "Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis". Alimentary Pharmacology & Therapeutics. 54 (11–12): 1405–1415. doi:10.1111/apt.16664. ISSN 1365-2036. PMC 9298378. PMID 34671996.
^ Stemmer, Salomon M.; Manojlovic, Nebojsa S.; Marinca, Mihai Vasile; Petrov, Petar; Cherciu, Nelly; Ganea, Doina; Ciuleanu, Tudor Eliade; Pusca, Ioana Adriana; Beg, Muhammad Shaalan; Purcell, William T.; Croitoru, Adina-Emilia; Ilieva, Rumyana Nedyalkova; Natošević, Sladjana; Nita, Amedeia Lavinir; Kalev, Dimitar Nikolaev; Harpaz, Zivit; Farbstein, Motti; Silverman, Michael H.; Bristol, David; Itzhak, Inbal; Fishman, Pnina (7 January 2021). "Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial". Cancers. 13 (2): 187. doi:10.3390/cancers13020187. ISSN 2072-6694. PMC 7825785. PMID 33430312.
^ Fishman, Pnina; Bareket-Samish, Avital; Itzhak, Inbal (1 June 2023). "Effects of namodenoson on pancreatic carcinoma: Preclinical evidence". Journal of Clinical Oncology. 41 (16_suppl): e15134. doi:10.1200/JCO.2023.41.16_suppl.e15134. S2CID 259081369.

[1] Safadi, Rifaat; Braun, Marius; Francis, Adi; Milgrom, Yael; Massarwa, Muhammad; Hakimian, David; Hazou, Wadi; Issachar, Assaf; Harpaz, Zivit; Farbstein, Motti; Itzhak, Inbal; Lev-Cohain, Naama; Bareket-Samish, Avital; Silverman, Michael H.; Fishman, Pnina (December 2021). "Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis". Alimentary Pharmacology & Therapeutics. 54 (11–12): 1405–1415. doi:10.1111/apt.16664. ISSN 1365-2036. PMC 9298378. PMID 34671996.

[2] Stemmer, Salomon M.; Manojlovic, Nebojsa S.; Marinca, Mihai Vasile; Petrov, Petar; Cherciu, Nelly; Ganea, Doina; Ciuleanu, Tudor Eliade; Pusca, Ioana Adriana; Beg, Muhammad Shaalan; Purcell, William T.; Croitoru, Adina-Emilia; Ilieva, Rumyana Nedyalkova; Natošević, Sladjana; Nita, Amedeia Lavinir; Kalev, Dimitar Nikolaev; Harpaz, Zivit; Farbstein, Motti; Silverman, Michael H.; Bristol, David; Itzhak, Inbal; Fishman, Pnina (7 January 2021). "Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial". Cancers. 13 (2): 187. doi:10.3390/cancers13020187. ISSN 2072-6694. PMC 7825785. PMID 33430312.

[3] Fishman, Pnina; Bareket-Samish, Avital; Itzhak, Inbal (1 June 2023). "Effects of namodenoson on pancreatic carcinoma: Preclinical evidence". Journal of Clinical Oncology. 41 (16_suppl): e15134. doi:10.1200/JCO.2023.41.16_suppl.e15134. S2CID 259081369.

[1]

[2]

[3]